Pharmaceuticals

SIHUAN PHARM

SIHUAN PHARM released FY2025 9 Months Earnings on March 31 (BJT), actual revenue HKD 2.046 B, actual EPS HKD 0.0166

SIHUAN PHARM released FY2025 Q3 earnings on March 31 (BJT), actual revenue HKD 804.46 M, actual EPS HKD 0.0046

SIHUAN PHARM released FY2025 Q4 earnings on March 31 Pre-Market (BJT), actual revenue HKD 818.35 M, actual EPS HKD 0.0047

SIHUAN PHARM released FY2025 earnings on March 31 Pre-Market (BJT), actual revenue HKD 2.861 B (forecast HKD 2.841 B), actual EPS HKD 0.0215 (forecast HKD 0.0333)

SIHUAN PHARM to Release FY2025 Annual Earnings on March 31, Pre-Market BJT, Forecast Revenue HKD 2.891 B, EPS HKD 0.0339

SinoUnion Pharmaceutical's Innovative Drug Pyrolisib Approved for New Indication

Cihuan Pharmaceutical expects a net profit of no less than 150 million yuan in 2025, aesthetic medical business sees rapid growth

Meiyan Space Biotech Co., Ltd. Receives Approval for New Specifications of Polylactic Acid Facial Filler

Sinopharm's Pyrolacitib Inclusion in National Health Insurance Directory for the First Time

ChinaRx Pharmaceuticals and AbaloneBio Sign Cooperation Agreement to Jointly Develop Next-Generation Obesity Treatment Drugs

Four Ring Medical Completed Acquisition and Subsidiary IPO with Breakthrough

PharmaChina International Repurchased 15 Million Shares

Sinopharm Central Asia Repurchased 10 Million Shares

Sinopharm Four Ring invests in Suisselle to deepen global aesthetic market layout

Huiminpharmaceutical Obtains Registration Certificate for 'Freeze Youth'

Medi-Max's Meiyanspace Receives Approval for Freezain Hyaluronic Acid Composite Solution

CSIPharma repurchased 1.5 million shares for HKD 2.22 million

Sinopharm Four Ring Announces Share Guarantee Quota Benchmark

Huise Biopharma's P052 Injection Receives Clinical Trial Approval

Cathaya Pharmaceutical repurchased 13,096,000 shares for HKD 19.572 million

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

00460

02575

Sihuan Pharmaceutical's subsidiary, Xuanzhu Biopharm, has completed the full circulation of its H shares, converting over 357 million previously unlisted shares. This brings Xuanzhu's total issued share capital to nearly 518 million H shares on the Hong Kong Stock Exchange. The move enhances liquidity and market access, supporting Sihuan's strategy in the biopharmaceutical sector. Sihuan, founded in 2001 and listed since 2010, focuses on innovative drugs and aims to lead in medical aesthetics and biopharma in China.

Tip Ranks

XUANZHUBIO-B

Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong

Sihuan Pharmaceutical Holdings Group announced promising early results from the Phase 1b FORTRESS trial of NG-350A for locally advanced rectal cancer. The trial showed a 50% clinical response rate in the first 10 patients, significantly higher than the typical 25% with standard treatment. No serious adverse events were reported, indicating a favorable safety profile. These findings may enhance treatment outcomes for high-risk patients and strengthen Sihuan's position in colorectal cancer therapies as they pursue further clinical trials in mainland China.

Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial

Sihuan Pharmaceutical's subsidiary, Xuanzhu Biopharm, announced promising Phase III trial results for its ALK inhibitor dirozalkib in treating ALK-positive advanced non-small cell lung cancer. The trial demonstrated that dirozalkib significantly improved median progression-free survival compared to crizotinib, along with better response rates and safety profiles. This strengthens Xuanzhu's oncology portfolio and supports Sihuan's innovative drug strategy. The company is focused on developing first-in-class medicines and has a market cap of HK$13.53B, with a year-to-date price performance of 17.89%.

First Trust NYSE Arca Biotech Index Fd

Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib

560600

159506

513700

159102

513120

516500

588130

159316

Xuanzhu Biopharmaceutical Co., Ltd. has received approval from China's drug regulator to initiate a Phase III trial for its Anaprazole Sodium Enteric-coated Tablets aimed at eradicating Helicobacter pylori. The study will involve 556 adults and compare the efficacy of anaprazole-based therapy against esomeprazole. This trial is part of Xuanzhu's strategy to expand its presence in the gastrointestinal market, targeting a treatment market projected to reach RMB5.5 billion by 2024. The company aims to enhance its role in digestive disease treatments and capitalize on the growing demand for safer proton pump inhibitors in China.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Minsheng Royal CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori

In a report released on April 8, from Citic Securities maintained a Buy rating on Sihuan Pharmaceutical Holdings Group, with a price target of HK$2.00. The company’s shares closed last Friday at HK$1.44.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Sihuan Pharmaceutical Holdings Group is a Moderate Buy with an average price target of HK$2.04.

Sihuan Pharmaceutical Holdings Group (SHPHF) Gets a Buy from Citic Securities

Hong Kong's innovative drug sector is experiencing significant growth, with companies like Ascletis Pharmaincreasing over 3% and Hansoh Pharmaceuticalrising by more than 2%. Other firms, including WuXi AppTecand Sihuan Pharmaceutical, are also showing upward trends.

CoinLive

China Universal CNI HK Connect Innovative Drugs Industry ETF

HANSOH PHARMA

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ASCLETIS-B

WUXI APPTEC

Hong Kong's Innovative Drug Sector Gains Momentum

Sihuan Pharmaceutical Holdings Group (HK:0460) reported a significant rebound in 2025, with revenue rising 37.7% to RMB2.62 billion and gross profit increasing 45.1% to RMB1.80 billion, resulting in a gross margin of 68.8%. The medical aesthetics segment became the largest business, nearly doubling its revenue to RMB1.49 billion. Despite a 13% decline in the generic drug segment, the company is strategically pivoting towards high-growth aesthetics and innovative therapies. The current analyst rating for the stock is a Hold with a price target of HK$1.50.

Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins

SIHUAN PHARM announced its full-year results for the year ended December last year, with a revenue of RMB 2.618 billion, an increase of 37.7% year-on-year. It turned a loss into a profit of RMB 180 million, compared to a loss of RMB 217 million in the same period last year; earnings per share were 1.97 cents. A final dividend of 0.96 cents was declared, compared to no dividend in the same period last year

AASTOCKS

"Performance" SIHUAN PHARM turned a loss into a profit of 180 million RMB for the whole year, with a final dividend of 0.96 cents RMB

SIHUAN PHARM(00460.HK)